- The European Commission has approved AstraZeneca Plc AZN and Daiichi Sankyo's DSNKY Enhertu as monotherapy for unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
- The approval is based on results from the DESTINY-Breast03 Phase 3 trial, in which Enhertu reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1).
- Additional results from the DESTINY-Breast03 Phase 3 trial showed that in the secondary endpoint of overall survival (OS), there was a strong trend towards improved OS with Enhertu; however, this analysis is not yet mature and further follow-up is ongoing.
- Related: Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer.
- Nearly all patients treated with Enhertu were alive at nine months compared to 91.3% of patients treated with T-DM1. The confirmed objective response rate was more than doubled in the Enhertu arm versus the T-DM1 arm (79.7% vs. 34.2%).
- Following EU approval, AstraZeneca will pay $75 million to Daiichi Sankyo as a milestone payment.
- Price Action: AZN shares are up 1.46% at $67.34 during the premarket session on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.